|
|
| Line 1: |
Line 1: |
| {{drugbox
| | #REDIRECT [[Isradipine#Pharmacology]] |
| | IUPAC_name = methyl propan-2-yl 2,6-dimethyl-4- (8-oxa-7,9-diazabicyclo[4.3.0] nona- 2,4,6,9- tetraen- 5-yl)- 1,4-dihydropyridine- 3,5-dicarboxylate
| |
| | image = Isradipine_svg.png
| |
| | CAS_number = 75695-93-1
| |
| | ATC_prefix = C08
| |
| | ATC_suffix = CA03
| |
| | ATC_supplemental =
| |
| | PubChem = 3784
| |
| | DrugBank = APRD00298
| |
| | C=19 | H=21 | N=3 | O=5
| |
| | molecular_weight = 371.387 g/mol
| |
| | bioavailability =
| |
| | protein_bound = 95%
| |
| | metabolism =
| |
| | elimination_half-life = 8 hours
| |
| | excretion =
| |
| | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| |
| | pregnancy_US = <!-- A / B / C / D / X -->
| |
| | pregnancy_category =
| |
| | legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| |
| | legal_UK = <!-- GSL / P / POM / CD -->
| |
| | legal_US = <!-- OTC / Rx-only -->
| |
| | legal_status =
| |
| | routes_of_administration =
| |
| }}
| |
| {{CMG}}
| |
| | |
| | |
| | |
| ==[[Isradipine (patient information)|For patient information, click here]]==
| |
| | |
| ==Overview==
| |
| '''Isradipine''' (tradenames '''DynaCirc''', '''Prescal''') is a [[calcium channel blocker]] of the [[dihydropyridine]] class. It is usually prescribed for the treatment of [[high blood pressure]] in order to reduce the risk of [[stroke]] and [[heart attack]]. More recent research suggests that isradipine may have potential uses for treating [[Parkinson's disease]] (Chan et al, 2007).
| |
| | |
| ==Further reading==
| |
| <div class="references-small">
| |
| <references/>
| |
| * {{cite journal | author = Hattori T, Wang P | title = Calcium antagonist isradipine-induced calcium influx through nonselective cation channels in human gingival fibroblasts. | journal = Eur J Med Res | volume = 11 | issue = 3 | pages = 93-6 | year = 2006 | id = PMID 16751108}}
| |
| * {{cite journal | author = Ganz M, Mokabberi R, Sica D | title = Comparison of blood pressure control with amlodipine and controlled-release isradipine: an open-label, drug substitution study. | journal = J Clin Hypertens (Greenwich) | volume = 7 | issue = 4 Suppl 1 | pages = 27-31 | year = 2005 | id = PMID 15858400}}
| |
| * {{cite journal | author = Johnson B, Roache J, Ait-Daoud N, Wallace C, Wells L, Dawes M, Wang Y | title = Effects of isradipine, a dihydropyridine-class calcium-channel antagonist, on d-methamphetamine's subjective and reinforcing effects. | journal = Int J Neuropsychopharmacol | volume = 8 | issue = 2 | pages = 203-13 | year = 2005 | id = PMID 15850499}}
| |
| * {{cite journal | author = Fletcher H, Roberts G, Mullings A, Forrester T | title = An open trial comparing isradipine with hydralazine and methyl dopa in the treatment of patients with severe pre-eclampsia. | journal = J Obstet Gynaecol | volume = 19 | issue = 3 | pages = 235-8 | year = 1999 | id = PMID 15512286}}
| |
| </div>
| |
| | |
| * C. Savio Chan, Jaime N. Guzman, Ema Ilijic, Jeff N. Mercer, Caroline Rick, Tatiana Tkatch, Gloria E. Meredith, D. James Surmeier (2007) [http://www.nature.com/nature/journal/vaop/ncurrent/abs/nature05865.html Rejuvenation protects neurons in mouse models of Parkinson's disease.] Nature. Nature advance online publication 10 June 2007 | doi:10.1038/nature05865
| |
| | |
| ==External links==
| |
| * {{MedlinePlusDrugInfo|medmaster|a693048}}
| |
| * {{DiseasesDB|30003}}
| |
| * [http://news.bbc.co.uk/1/hi/health/6740109.stm Drug offers hope for Parkinson's] - BBC News, 11 June 2007.
| |
| | |
| {{Calcium channel blockers}}
| |
| | |
| [[Category:Calcium channel blockers]]
| |
| [[Category:Drugs]]
| |
| | |
| [[de:Isradipin]]
| |
| [[fr:Isradipine]] | |
| | |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |